This phase II trial is evaluating the safety and effectiveness of an immunotherapy (Pembrolizumab) in patients with high risk, non-muscle invasive bladder cancer, who have not responded to prior therapy.
This trial is treating patients with bladder cancer.
This is a systemic therapy trial.
You may be able to join this trial if:
- You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have been diagnosed with a prior or secondary type of cancer.
- You have had certain treatments, surgical procedures or drugs.
- You have previously been treated (or are currently being treated) on a clinical trial.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Trial Identifiers
Use the hyperlinks, where available to access additional clinical trial information.
Scientific Title
A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Subjects With High Risk Non-muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy
Commercial Sponsor
Merck
Summary
All participants will receive intravenous Pembrolizumab (200mg) once every three weeks, for up to two years.
Recruiting Hospitals Read More
Not Recruiting Hospitals Read More
Closed